- Home
- XENE vs ZLAB Comparison
XENE vs ZLAB Comparison
Compare XENE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | ZLAB |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.0B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XENE | ZLAB |
|---|---|---|
| Price | $45.01 | $18.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $53.91 | ★ $57.22 |
| AVG Volume (30 Days) | 777.9K | ★ 937.7K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,500,000.00 | ★ $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $26.74 | $16.82 |
| 52 Week High | $46.60 | $44.34 |
Technical Indicators
Market Signals| Indicator | XENE | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 42.03 |
| Support Level | $42.44 | $17.37 |
| Resistance Level | $46.25 | $18.29 |
| Average True Range (ATR) | 1.31 | 0.65 |
| MACD | 0.02 | 0.27 |
| Stochastic Oscillator | 61.78 | 51.76 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.